Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes

References

• The Emerging Risk Factor Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;313:52–60.
   Google Scholar
• The Emerging Risk Factor Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222.
   PubMed Web of Science ®Google Scholar
• Saydah S, Eberhart M, Loria C, et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156:714–719.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureases or insulin with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
   PubMed Web of Science ®Google Scholar
• Evans J, Ogston S, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930–936.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Eng J Med. 2011;364:818–828.
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Eng J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• ACCORD study group writing committee. 9-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016;39:701–708.
   PubMed Web of Science ®Google Scholar
• Yabe D. Cardiovascular safety trials of incretin-based drugs: what do they mean. J Diabetes Investig. 2017;8:272–276.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015;371:2117–2128.
   Google Scholar
• Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Eng J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Eng J Med. 2015;373:2247–2257.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y. Incretin actions beyond the pancreas: lessons from knockout mice. Curr Opin Pharmacol. 2013;13:946–953.
   PubMed Web of Science ®Google Scholar
• Marso S, Daniels G, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Eng J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Mann J, Orsted D, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839–848.
   PubMed Web of Science ®Google Scholar
• Poulter N, Mann J, Fonseca V, et al. Liraglutide reduces major cardiovascular evenrts in patients with chronic kidney disease: results from the LEADER trial. Circulation. 2017;136:A15035Mann.
   Google Scholar
• Guthrie R. Practice pearl: empagliflozin reduces cardiovascular events and mortality in type 2 diabetes. Postgrad Med. 2016;128:335–337.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani M, DeFronzo R, Del Prato S, et al. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care. 2017;40:813–820.
   PubMed Web of Science ®Google Scholar
• Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a preview of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017;40:821–831.
   PubMed Web of Science ®Google Scholar
• Yabe D, Nishikino R, Kaneko M, et al. Short-term inpacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf. 2015;14:795–800.
   PubMed Web of Science ®Google Scholar
• Scirica B, Bhatt D, Braunwald E. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Eng J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Green J, Bethel M, Armstrong P, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Eng J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• White W, Cannon C, Heller S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Eng J Med. 2013;369:327–335.
   Web of Science ®Google Scholar
• Marco S, Bain S, Console A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Rizvi A, Parti A, et al. Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovasc Diabetal. 2016;15:162–169.
   PubMed Web of Science ®Google Scholar
• Marguiles K, Hernandez A, Redfield M, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–508.
   PubMed Web of Science ®Google Scholar
• Seino Y, Yabe D, Sasaki T, et al. Sodium-glucose cotransporter-2 inhibitor lusegliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52 week open-label, single-arm study. J Diabetes Investig. 2017. DOI:10.1111/jdj.12694/
   Google Scholar
• Mahaffey K, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2017. Published online November 13, 2017. Available from: http://circ.ahajournals.org/content/early/2017/11/11/CIRCULATIONAHA.117.032038
   Web of Science ®Google Scholar